Target and model assessment
Assess target location, intensity and heterogeneity, then define model-selection criteria.
Application
Antibody, multispecific & TCE studies
Compare antibody, multispecific and TCE responses in human tumor organoids, using target expression and immune activation to explain differences.
- Model fitSelect PDO or PDO 2.0 for the tumor and immune context
- Target statusCheck the candidate target and controls
- Effector setupDefine cell source and E:T ratio
- Functional assaysCompare killing, activation and cytokine readouts
APPLICATION PATH
Choose the study combination from tumor and immune context
Conventional PDOs support standardized tumor-killing comparisons. When tissue architecture or sample-associated immune context matters, PDO 2.0 / ALI can add that layer alongside mechanism-matched effector cells and functional endpoints.
PDO 2.0 model images
Design antibody studies around tumor and T-cell context
PDAC PDO 2.0 images show epithelial and T-cell markers; renal PDO 2.0 images show PanCK and CD3 signals during culture. Candidate studies can add effector-cell, killing and immune-activation assays matched to the mechanism.
View imagePDAC tissue and PDO comparison: H&E and bright-field images show tissue morphology; CK19 labels epithelial cells and CD3 labels sample-associated T cells.
TRiCBIO PDAC PDO 2.0 study data
View imageTissue and model context: PanCK, CD3 and DAPI imaging compares tumor-epithelial and CD3-positive immune-cell signals across the source tissue and PDO culture time points.
TRiCBIO ccRCC PDO 2.0 immune-context study dataReview the related model studies
Continue to the PDAC and renal PDO 2.0 studies for model context and immune-assay evidence.
Study focus
Questions we can help answer
- 01How does target expression support model selection?
- 02What target-dependent killing occurs with the selected effectors?
- 03How do activation, killing and cytokine readouts support one another?
Study workflow
From study goal to results
Effector and control design
Define effector source, E:T ratio, preconditioning and target-relevant positive and negative controls.
Killing and immune activation
Combine live or endpoint imaging, viability/apoptosis, activation markers such as CD107a and cytokines.
Candidate comparison
Rank candidates by potency, response window and immune-activation profile under matched conditions.
Model options
Models for your study
We tailor the effector-cell source, E:T ratio and controls to the target and molecular format so killing, activation and cytokine readouts can support candidate comparison together.
PROJECT DISCUSSION
Plan an antibody, multispecific or TCE study
With the target, molecular format, tumor model and effector-cell conditions defined, we can design the relevant killing and activation comparisons.